AKT1 and cancer: Targeting senescence is also a more promising approach to treat cancers, as suggested by Sin S et al., who delivered chronic treatment with sub-apoptotic concentrations of 20(S)-Rg3 to induce ROS production via Akt activation and p53/p21-dependent senescence-like growth arrest in glioma cells (Sin et al., 2012).